Sertoli-Leydig Cell Tumor
Symptoms, Doctors, Treatments, Advances & More

Learn About Sertoli-Leydig Cell Tumor

What is the definition of Sertoli-Leydig Cell Tumor?

Sertoli-Leydig cell tumor (SLCT) is a rare cancer of the ovaries. The cancer cells produce and release a male sex hormone called testosterone.

What are the alternative names for Sertoli-Leydig Cell Tumor?

Sertoli-stromal cell tumor; Arrhenoblastoma; Androblastoma; Ovarian cancer - Sertoli-Leydig cell tumor

What are the causes of Sertoli-Leydig Cell Tumor?

The exact cause of this tumor is not known. Changes (alterations) in genes may play a role.

SLCT occurs most often in young women 20 to 30 years old. But the tumor can occur at any age.

What are the symptoms of Sertoli-Leydig Cell Tumor?

The Sertoli cells are normally located in the male reproductive glands (the testes). They feed sperm cells. The Leydig cells, also located in the testes, release a male sex hormone.

These cells are also found in a woman's ovaries, and in very rare cases lead to cancer. SLCT starts in the female ovaries, mostly in one ovary. The cancer cells release a male sex hormone. As a result, the woman may develop symptoms such as:

  • A deep voice
  • Enlarged clitoris
  • Facial hair
  • Loss in breast size
  • Stopping of menstrual periods

Pain in the lower belly (pelvic area) is another symptom. It occurs due to the tumor pressing on nearby structures.

Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Sertoli-Leydig Cell Tumor?

Surgery is done to remove one or both ovaries.

If the tumor is at an advanced stage, chemotherapy or radiation therapy may be done after surgery.

Who are the top Sertoli-Leydig Cell Tumor Local Doctors?
Elite in Sertoli-Leydig Cell Tumor
Elite in Sertoli-Leydig Cell Tumor
Referral may be required
Montreal, QC, CA 

William Foulkes practices practicing medicine in Montreal, Canada. Mr. Foulkes is rated as an Elite expert by MediFind in the treatment of Sertoli-Leydig Cell Tumor. He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Sertoli-Leydig Cell Tumor, Ovarian Cancer, DICER1 Syndrome, Oophorectomy, and Mastectomy.

Distinguished in Sertoli-Leydig Cell Tumor
Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Obstetrics and Gynecology
Referral may be required

Endeavor Health Medical Group

880 W. Central Rd., Suite 5000, 
Arlington Heights, IL 
Languages Spoken:
English, German, Italian
Accepting New Patients
Offers Telehealth

Ernst Lengyel is an Obstetrics and Gynecologist practicing medicine in Arlington Heights, Illinois. Dr. Lengyel is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Sertoli-Leydig Cell Tumor, Endometrial Cancer, Oophorectomy, and Splenectomy. Dr. Lengyel is board certified in American Board Of Obstetrics And Gynecology, Practicing Since1992, and Gynecologic Oncology. Dr. Lengyel is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Sertoli-Leydig Cell Tumor
Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Obstetrics and Gynecology
Referral may be required

UChicago Medicine Orland Park

14290 S. La Grange Rd., 
Orland Park, IL 
Languages Spoken:
English, Turkish
Accepting New Patients
Offers Telehealth

John Moroney is an Obstetrics and Gynecologist practicing medicine in Orland Park, Illinois. Dr. Moroney is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Gastrostomy, and Bladder Reconstruction. Dr. Moroney is board certified in Gynecologic Oncology, American Board Of Obstetrics Gynecology, and Practicing Since2002. Dr. Moroney is currently accepting new patients.

What is the outlook (prognosis) for Sertoli-Leydig Cell Tumor?

Early treatment results in a good outcome. Feminine characteristics usually return after surgery. But male characteristics resolve more slowly.

For more advanced stage tumors, the outlook is less positive.

What are the latest Sertoli-Leydig Cell Tumor Clinical Trials?
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Background: \- Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age. Recently, it has been shown that this condition can be inherited (e.g., mutation of the DICER1 gene). Researchers are studying both clinical and genetic aspects of this newly described condition. They are interested i...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...

Who are the sources who wrote this article ?

Published Date: May 01, 2026
Published By: Warren Brenner, MD, Oncologist, Lynn Cancer Institute, Boca Raton, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Beffa LB, Sung CJ, DiSilvestro PA. Germ cell, stromal, and other ovarian tumors. In: Creasman WT, Mutch DG, Mannel RS, Tewari KS, eds. DiSaia and Creasman Clinical Gynecologic Oncology. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 10.

Einhorn LH. Testicular cancer. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 185.

Friedlander TW, Small E. Testicular cancer. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 83.

Smith RP. Sertoli-Leydig cell tumor (arrhenoblastoma). In: Smith RP, ed. Netter's Obstetrics & Gynecology. 4th ed. Philadelphia, PA: Elsevier; 2024:chap 165.

Stephenson AJ, Gilligan TD. Neoplasms of the testis. In: Dmochowski RR, Kavoussi LR, Peters CA, et al, eds. Campbell-Walsh-Wein Urology. 13th ed. Philadelphia, PA: Elsevier; 2026:chap 79.